Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas

NCT ID NCT07691450

Not yet recruiting Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dose and see whether the combinations can shrink tumors. The study enrolls adults with several subtypes of T-cell lymphoma, including peripheral and cutaneous forms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belinostat combined with azacitidine or pralatrexate
What this could lead to
If successful, this could provide new treatment options for people with T-cell lymphoma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the combinations may prove too toxic or ineffective. Results may not apply to all lymphoma subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma hepatosplenic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma primary cutaneous gamma-delta t-cell lymphoma primary cutaneous gamma/delta-positive T-cell lymphoma subcutaneous panniculitis-like T-cell lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ANAPLASTIC LARGE CELL LYMPHOMA RECURRENT ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, FOLLICULAR-TYPE RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED RECURRENT HEPATOSPLENIC T-CELL LYMPHOMA RECURRENT MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA RECURRENT MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA RECURRENT PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED RECURRENT PRIMARY CUTANEOUS CD8-POSITIVE AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA RECURRENT PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA RECURRENT SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA REFRACTORY ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA, FOLLICULAR-TYPE REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY HEPATOSPLENIC T-CELL LYMPHOMA REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA REFRACTORY MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY PRIMARY CUTANEOUS CD8-POSITIVE AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA REFRACTORY PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA REFRACTORY SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.